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ABSTRACT OF THE DISSERTATION
Survivin: Regulation by YY1 and Role in Pancreatic Cancer Combination Therapy
by
Nicholas R. Galloway
Doctor of Philosophy, Graduate Program in Biochemistry
Loma Linda University, March 2014
Dr. Nathan Wall, Chairperson
Despite significant clinical and basic science advancements, cancer remains a
devastating disease that affects people of all ages, races, and background. Survivin, the
fourth most common transcript found in cancer cells, is a protein that is thought to be
involved in the enhanced proliferation, survival, and metastasis of cancer cells.
Therefore understanding how this gene is regulated is potentially of vital importance to
improving cancer management and therapy. Our work has identified a novel
transcriptional regulator of survivin called Yin Yang 1 (YY1). YY1 is a transcription
factor that has been observed to activate some gene promoters and repress others, and it is
gaining increasing interest as a target of cancer therapy. Our work shows for the first
time that YY1 is a repressor of survivin transcription and can do so by physically
interacting with the survivin promoter. Furthermore, YY1 appears to contribute to basal
survivin transcriptional activity, indicating that disruption of its binding may in part
contribute to survivin overexpression after cellular stress events including chemo- and
radiotherapy. It is also important to use gained mechanistic understandings of cancer
initiation and progression to design logical new approaches to cancer therapy. Pancreatic
cancer is one of the most deadly forms of cancer known, and survivin expression has
been observed to be an important factor in pancreatic cancer aggressiveness or resistance
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to therapy. Therefore survivin downregulation may represent an important means of
gaining improved treatment efficacy in pancreatic cancer. Using combined gemcitabine
and proton radiation therapy, we show that downregulation of survivin and its family
member X-linked IAP may lead improved cell death following treatment, particularly
when gemcitabine therapy is instituted prior to proton radiotherapy.
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CHAPTER ONE
INTRODUCTION

Cancer Facts and Figures
Cancer is one of the most devastating diseases in the world, and one that has
touched the lives of nearly every family and individual in the United States. The
National Cancer Institute estimates that in January 2012 there were an estimated 13.7
million individuals living in the United States that had a personal history of cancer. The
projected number of new cases of cancer in 2013 is 1,660,290. It is the second most
common cause of death, accounting for approximately 1 in 4 deaths in the United States.
Furthermore, 580,350 individuals are projected to die as a result of cancer in 2013.
Figure 1 illustrates the death rates for males (A) and females (B) from 1930-2009.
Fortunately, progress has been made in detection and treatment of cancer, resulting in an
increase in overall 5-year cancer survival of 68% between 2001-2008 up from 49%
between 1975-1977.
Cancer also imposes an enormous financial burden on the United States. The
National Institutes of Health estimate the overall cost of all cancers in 2008 to be $201.5
billion: $77.4 billion for direct medical costs and $124 billion for indirect costs related to
premature death and lost productivity1.

1

Figure 1. Age-adjusted cancer death rates, 1930-2009. Upper panel shows values for
males, lower panel shows values for females. Adapted from American Cancer Society
Cancer Facts and Figures 2013 1.

2

The leading cause of cancer death in 2013 was lung and bronchus cancer for both
men and women. However, prostate and breast cancer continue to have the highest
incidence in men and women, respectively. Pancreatic cancer, a disease of particular
importance to the chapter 3 of this dissertation, has presented a particularly large
challenge to cancer biologists and oncologists, as it continues to be one of the most lethal
cancers. Pancreatic cancer will cause an estimated 38,460 deaths in 2013, occuring
almost equally in men and women (Figure 2). From 2001-2007, the 5 year survival rate
for pancreatic cancer (all stages) was 6%. Since 2004, the overall incidence of pancreatic
cancer has been increasing by 1.5% per year.

3

Figure 2. Leading new cancer cases and deaths-2013. The estimated number of new
cases for males vs. females is shown of the left, and esimates for cancer deaths in males
vs. females is shown on the right. Adapted from American Cancer Society Cancer Facts
and Figures 2013 1.
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The figures shown above illustrate that some of the advances made in clinical and
basic science are indeed making an impact. However, they simultaneously depict a
disease in which scientists may be winning battles, but are clearly still losing the war.
This dissertation will explain work that has been done regarding the regulation of a
dysregulated cancer gene called survivin that may very well be a key to moving past
incremental, small victories in the fight against cancer onto large changes in how cancer
of all types is treated, and hopefully one day eradicated. It will also present work that
was aimed to take advantage of the James M. Slater Proton Treatment and Research
Center facility at Loma Linda University Medical Center by providing evidence for an
alternative and potentially more efficacious approach to pancreatic cancer treatment.

The Inhibitor of Apoptosis Survivin
Survivin controls diverse cellular functions including surveillance checkpoints,
suppression of cell death, the regulation of mitosis, and the adaptation to unfavorable
environments 2-5. Its suppression of cell death activities and the baculovirus IAP repeat
(BIR) domain characterize it as a member of the inhibitor of apoptosis (IAP) family of
proteins 6. However, its lack of a COOH-terminal RING finger domain and the caspase
recruitment domain 7 make it structurally unique among the mammalian IAPs. The
overall multifaceted functionality of survivin is still being intensely scrutinized, though it
appears that protein compartmentalization plays an important role. Survivin has been
shown to colocalize in the mitochondria where it abolishes tumor cell apoptosis and
promotes tumorigenesis in immunocompromised animals 8. It, therefore, may possess a
role in apoptosis similar to the pro-apoptotic Bcl-2 family of proteins. Survivin has also
been found in the nucleus and cytosol where it has roles in mitosis regulation and
5

apoptosis inhibition, respectively 9. Survivin has been observed to be expressed in most
common human cancers and, while present during embryonic and fetal development,
survivin is undetectable in a variety of adult tissues 10. Its aberrant, high protein
expression in cancer cells and concomitantly low expression in most normal tissues
makes survivin an important anticancer target 11.
The accumulated data from the characterization of survivin expression in human
cancer tissues reveals an overwhelming consistent observation that the expression of
survivin is enhanced in various human cancers in comparison with the adjacent normal
tissue. Multiple therapeutic strategies have been successfully investigated including the
molecular antagonists such as antisense oligos, RNA inhibition, dominant negative
mutants, survivin-specific cytolytic T cells, a nonphosphorylatable survivin mutant
Thr34 Ala (T34A), and, most recently, binding interface mimetics 12-19. The observation
that a pool of survivin is localized extracellularly and is linked to erosive joint disease in
a significant fraction of rheumatoid arthritis patients, and that an autoimmune response
(survivin-targeting antibodies) to survivin correlates with protection from joint disease
20,21

provides evidence that anti-survivin therapy may be possible in other pathologies

such as cancer. Work in our laboratory is currently defining the role of exosomal
survivin in regulation of the tumor microenvironment 22.
While many different therapeutic approaches have been employed, few have been
aimed at regulation of survivin transcription. This is owed in large part to the complexity
of mechanisms involved in epigenetic, transcriptional, and post-transcriptional gene
regulation. It will likely require uncovering of all or most aspects of the machinery
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involved in aberrant gene regulation to reach the goal of developing personalized medical
approaches to treating unique cancer types.

Survivin Transcription
Survivin transcription is critical in embryogenesis, but is normally turned off in
adult life 23. However, survivin can be transcriptionally upregulated in adult life and
often results in disease, particularly cancer. Survivin is the fourth-most frequently
overexpressed transcript in most human cancers 24, and the specificity of the survivin
promoter for regulation in cancerous tissue has been demonstrated numerous times. It is
currently being investigated as a means of driving expression of therapeutic genes 25-27
because its high degree of specificity to malignant cells which could decrease off target
expression  of  a  suicide  gene  or  other  forms  of  gene  therapy.    Survivin’s  robust  and  
specific upregulation in cancer implies that the transcription factors involved in survivin
transcription must be present and themselves upregulated in cancerous tissue. Table 1
summarizes the role of several key transcription factors in survivin transcriptional
regulation.

7

Table 1: Summary of Key Transcriptional Regulators of
Survivin (modified from Zhang et al., 2006.
Key info and current
status

Pathway
NF-KB
p53
APC/Beta catenin/TCF-4
HIF-1
Sp1-DNA

Regulates survivin, but
mechanism unclear
Transcriptionally
downregulates survivin
APC dowregulates survivin
by inhibiting Bcatenin/TCF-4
Transcriptionally
upregulates survivin
Interference of Sp1
interaction-survivin
interaction downregulates
survivin
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Activators of Survivin Transcription
Survivin transcription is induced in part by the presence of cellular stress such as
that induced by chemotherapeutic agents, radiotherapy, and aspects of the tumor
microenvironment. One such aspect of the tumor microenvironment that is common to
most solid tumors is hypoxia and subsequent induction of neovascularization via VEGF
and HIF-1 activation. This has lead to investigation a possible relationship between the
hypoxia-responsive gene HIF-1 and survivin. A study from Wei et al. 28 found a strong
correlation between HIF-1 and survivin expression in immunohistochemically analyzed
pancreatic cancer samples. Follow up studies found that use of antisense HIF-1 in
pancreatic cancer BxPc-3 cells inhibited survivin expression and induced apoptosis in
cells 29. Peng et al. found an association between Epidermal Growth Factor (EGF)
overexpression and survivin overexpression 30. This EGF-related upregulation was
mediated by HIF-1 transcriptional activation of the survivin gene, even under normoxic
conditions. Bai et al. more recently identified a strong relationship between survivin
overexpression and HIF-1 overexpression in cervical cancer 31. They show HIF-1 responsive element independent upregulation of survivin reporter constructs, specifically
in the first 158 bp of the survivin promoter. Indeed HIF-1 -mediated upregulation of
survivin has now been observed in many cancer types including pancreatic, prostate 32,
cervical 31, non-small cell lung 33, laryngeal 34, and colorectal cancer 35. Efforts are
underway to evaluate the effectiveness of disruption of HIF-1 expression as a means to
sensitize cells to therapeutic modalities.
It is now known that basal survivin transcription requires Sp1 (more will be said
about Sp1 later in this dissertation) or KLF5 36,37, but there are numerous other

9

transcription factors and coactivators that are thought to drive high levels of survivin
transcription. NF-κB is one of these transcription factors. It is a complex of proteins that
are involved in inflammation, increased cell proliferation, metastasis, and inhibition of
apoptosis. One of the mechanisms by which it contributes to these phenotypes is by
transcriptional activation of survivin 38-40. Members of the signal transducers and
activators of transcription (STAT) family are also transcription factors capable of binding
and activating the survivin promoter 41.

Downregulation of Survivin Transcription
Several key proteins are also able to downregulate survivin transcription. In
addition  to  p53’s  critical  involvement  in  cell  cycle  checkpoint  regulation,  it  also  prevents  
the transcription of oncogenes such as survivin. Retinoblastoma (Rb) and E2F have
similar effects on survivin transcription 42. However, these genes are often silenced,
mutated, and/or nonfunctional in patients with cancer. Therefore identification of other
transcription factors that may negatively regulate survivin is of importance to cancer
therapy. Egr-1, a transcription factor that shares many similarities with YY1, has
previously been noted to be involved in cell cycle, death, and differentiation. Much like
YY1, Egr-1 can either act as an activator or repressor depending on the promoter in
question and the available coregulators with which it can interact. Egr-1 has a consensus
binding site that shares some overlap with the Sp1 transcription factor 43,44. Interestingly,
YY1 can also be repressive or activating depending on a number of factors, and it also
shares some overlap with Sp1 binding sites for some of its targets 45. This dissertation
will show that the transcription factor YY1 may be involved in direct transcriptional
repression of survivin, which may reveal a novel means of studying inhibition of survivin
10

transcription for therapeutic treatments.
Natural agents are gaining increasing interest as a means of distrupting oncogene
transcription, including survivin. YM155, a small molecule inhibitor of survivin, has
recently been investigated in Phase II clinical trials for a variety of cancers including
diffuse large B-cell lymphoma 46, prostate cancer 47, melanoma 48, and non-small cell
lung cancer 49 due to its previously observed ability to induce apoptosis and reduce tumor
bulk in various in vitro and in vivo models 50. This induction of cell death is thought to
be due, at least in part, to its ability to decrease survivin transcription, but the mechanism
by which it does this is still under investigation. Nakamura et al. 51 recently found a role
for interleukin enhancer-binding factor 3 (ILF3/NF110) in this observed inhibition of
survivin expression by YM155. They also found that in luciferase reporter experiments,
ILF3-dependent upregulation of reporter activity could be attenuated with YM155,
suggesting that ILF3/NF110 is a physiological target of YM155. Currently, clinical trials
are showing promise for YM155, particularly as a combination therapy to sensitize
tumors to existing therapies. Other natural agents are also showing potential for
disruption of survivin transcriptional activity. Specificity proteins Sp1, Sp3, and Sp4
have long been known to be important transcription factors involved in the
overexpression of survivin in human cancer. However, little progress has been made to
exploit this relationship for gains in therapeutic approaches to cancer. Recently,
curcumin was identified as a natural agent that inhibits the ability of Sp1, Sp3, and Sp4 to
activate survivin transcription 52. It appears to do so by generating reactive oxygen
species that upregulate repressors of Sp proteins ZBTB10 and ZBTB4, and
downregulation of the microRNAs mir-20a, mir-27a, and mir-17-5p, that are regulators
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of these Sp repressors. Interestingly, curcumin is also showing promise as a sensitizing
agent to ionizing radiation in Burkitt lymphoma and non-Hodgkin lymphoma 53,54. The
natural agents Resveratrol and Quercetin in combination (RQ) have also shown a similar
downregulation of Sp proteins and their targets, including survivin 55. Interestingly, the
authors  cite  RQ’s  antioxidant  capabilities  (as  opposed  to  curcumin’s  generation  of  
reactive oxygen species) as the potential reason for this observed repression of Sp protein
and their transcriptional targets such as survivin. These data further support the need for
continued efforts to develop therapeutic approaches to cancer that include disruption of
survivin transcriptional activation.

The Multifunctional Transcriptional Factor Yin Yang-1
Yin Yang-1 (YY1) is a 65-kDa ubiquitous multifunction transcription factor that
is a member of the GLI-Kruppel family of nuclear proteins 56-58. This family of proteins
plays roles in development and exerts much of its function through cell cycle regulation.
YY1 is a relatively unique transcription factor in that it can act by repressing some genes
and activate others by binding to the specific DNA  sequence  5’-CGCCATNTT-3’  57,59.
This phenomenon was noted first when it was shown that YY1, in the presence of the
adenovirus-derived protein called E1A, represses the AAV P5 promoter 60. When E1A is
not present, YY1 then activates transcription 61.
Reports suggest that YY1 is required for cell survival, as complete ablation of
YY1 results in lethality 62. Furthermore, array data suggests that YY1 has roles in cell
cycle, cell adhesion, and other markers of disease aggressiveness 63,64. As is true for
survivin, YY1 is increasingly found to be involved in cell death regulation via NF-κB.
Within the serum amyloid A gene, there is a binding site for NF-κB that was found to
12

overlap with a YY1 binding motif. Lu et al. showed that YY1 binding was able to
abrogate NF-κB binding and transcriptional activity. A similar binding site overlap was
observed in a cytomegalovirus promoter 65. This offers some indirect evidence of YY1
involvement in cell death, but more direct evidence is also emerging. Evidence suggests
that YY1 transcriptionally represses Fas, which in turn means that YY1 is a significant
factor in resistance to Fas-induced apoptosis 66. YY1 also appears to have a direct role in
resistance to tumor necrosis factor-related apoptosis inducing ligand (TRAIL). Recent
findings show a direct role for YY1 negatively regulating transcription of death receptor
5 (DR5), meaning YY1 is also a resistance factor for TRAIL-induced apoptosis 67.

YY1’s  Role  in  Human Cancer
YY1 is gaining increasing interest as a cancer-related transcription factor.
The oncogenic role of YY1 has been reviewed numerous times 68-70, yet many questions
remain. Consistent with its variable role as a transcription factor depending on a
multitude of cellular and molecular conditions, it appears to have a variable role in cancer
depending  on  what  type  of  cancer  is  being  studied.    Intriguingly,  YY1’s  role in some
cancers appears to promote longer patient survival, whereas in others it correlates with
poorer outcomes and shorter survival. Table 2 summarizes current findings regarding
YY1’s  role  in  various  cancer  types.    A  computational  analysis  of  YY1  expression in
numerous data sets that looked at a broad array of cancer types indicates a relative
increase in YY1 expression compared to expression in normal tissue. Seligson et al. have
shown that YY1 protein levels are higher in metastatic prostate cancer tissue than in
primary tumor. However, they also found a correlation with lower YY1 protein levels
and survival, suggesting that lower YY1 levels may lend a survival advantage to
13

metastatic cells 71. Further supporting a role for YY1 in prostate cancer formation, Deng
et al. found that in prostate cancer YY1 interacts with androgen receptor (AR) to promote
PSA transcription 72.
A similar association of YY1 with disease progression has been noted in
intraepithelial neoplasms and cervical cancer. YY1 expression in high-grade squamous
intraepithelial lesions is higher than in low-grade squamous intraepithelial lesions, a
finding also consistent with the observation that high expression correlates with the
presence of Human Papilloma Virus infection 73.
There are also many reports of a direct role for YY1 in aberrant cell cycle in
cancer. Numerous studies show that YY1 is involved in tumorigenesis via interactions
with the tumor suppressor p53. The general mechanism it appears to do this by is
interference of p53-dependent transcription of its target genes by competing for binding
to the ACAT sequence of promoters 74. Also, YY1 has been shown to be essential for
optimal interaction of MDM-2 and p53, which is required for MDM-2 ubiquitination of
p53 75. The importance of this finding cannot be overstated, as an estimated 50% of all
tumors have p53-inactivating mutations 76.
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Table   2:      YY1   expression   in   human   cancers   and   it’s   clinical   relevance   (modified   from  
Castellano et al. 68).
Tumor Type

Methods

Clinical relevance of
YY1 Overexpression

Reference

Positive correlation
with metastasis and
inverse relationship
with poor outcome

71

Positive correlation
with long-term survival

77

Prostate cancer

IHC

Ovarian cancer

Microarray

Ovarian c`ancer

Microarray, Positive correlation
IHC, RT- with survival and
PCR
response to taxanes

78

73

Cervical
neoplasms

RT-PCR

Positive correlation
with disease
progression

Osteosarcoma

RT-PCR,
IHC, WB

Positive correlation
with more malignant
phenotype

79

Myeloid
Leukemia

RT-PCR

Positive correlation
with t(8;21)

80

Non-Hodgkin
Lymphoma

RT-PCR

Positive correlation
with poor outcome

81

Follicular
Lymphoma

IHC

Positive correlation
with length of survival

82
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Pancreatic Cancer: Toward Improved Combination Therapy
Pancreatic cancer is the fourth leading cause of cancer-related death (refer to
Figure 2). Early detection of localized disease with subsequent surgical resection offers
virtually the only hope of long-term survival to pancreatic cancer patients.
Unfortunately, this represents only an estimated 10-20% of all patients. Because
chemotherapy has offered very minimal improvements in survival time, efforts to use
radiation in combination have been explored and been met with some success 83. Doses
for radiation therapy are limited, however, by the proximity of other structures that are
subject to bystander toxicity such as the liver, kidneys, stomach, spinal cord, and small
intestines. Proton radiotherapy is a powerful means of treating cancer as it offers the
advantage of allowing delivery of a given radiation dose at the depth of a tumor, but not
beyond. Thus, non-tumor tissue beyond the tumor is spared from radiation and the longterm complications of such exposure. If off-target damage can be reduced, the dose of
radiation used on the tumor can be increased to improve efficacy of the treatment.
Unfortunately, tumors can develop radioresistance due to changes in molecular
determinants of cell death.
Reports suggest that survivin is one factor involved in imparting radioresistance
to tumors. In a study of pancreatic duct cell carcinoma (PDC) vs. precancerous
intraductal papillary-mucinous tumor (IPMT), Satoh et al. found high survivin expression
in PDC as opposed to very low expression in IPMT, suggesting that survivin is involved
in the progression to a malignant phenotype in pancreatic cancer 84. A second facet of
this dissertation is exploration of combined therapy with gemcitabine and proton therapy.
Currently, proton therapy is used mostly for prostate, brain, and head and neck cancer.
This is largely due to ease of targeting these structures. However, efforts are underway to
16

evaluate the effectiveness of proton therapy for pancreatic cancer. A Phase II clinical
trial at Loma Linda University Medical Center is currently exploring the role of proton
therapy in combination with different chemotherapy regimens in locally advanced
pancreatic cancer treatment. In addition to advancing the understanding of potential
advantages of proton therapy in pancreatic cancer cell death, the work presented in
Chapter 3 presents evidence that survivin and its IAP family member X-linked IAP
(XIAP) may be key molecular determinants of apoptosis and radioresistance in pancreatic
cancer. If a viable means of modulating survivin and XIAP levels in a clinical setting is
discovered, this may offer a means of drastically improving response to therapy.

Design of Studies
The studies presented in the chapters to follow were designed to advance the
understanding of both basic science aspects of cancer biology and provide data to
improve the therapeutic approach to pancreatic cancer. Most effective cancer therapies
are based on a sound rationale that was developed from basic science research to discover
molecular and cellular behavior after manipulations, whether they are genetic, medicinal,
or immunological. Chapter 2 of this dissertation details a study of transcriptional
regulation of survivin in attempt to better understand factors involved in survivin
overexpression in cancer. To do this we used a luciferase reporter system that allows
one to study promoter activity in the presence of modifying factors including cellular
stress and transcription factor overexpression. Furthermore, we used electrophoretic
mobility shift assays (EMSA) to determine whether or not YY1 was capable of binding
directly to the survivin promoter. This is an important step to try to establish how a
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transcription factor is affecting target gene expression because it can do so by many
means aside from direct promoter binding.
In Chapter 3, the goal was to discover if different doses and timing of a
combination of gemcitabine and proton therapy could sensitize pancreatic cancer cell to
enhanced cell death, and to see if this enhanced cell death correlated with survivin
expression. To study cell death after each treatment combination, we used propidium
iodide flow cytometry and western blots to investigate the concomitant survivin
expression. We also chose to compare a radiosensitive cell line (MiaPaCa-2) with a
radioresistant cell line (Panc-1) to better define the usefulness of proton therapy in our
treatment schemes.
These studies, done in cell culture models, were designed to establish preclinical
rationales for later work to be done in animal models, or in the case of Chapter 3,
patients. As previously mentioned, efforts to develop therapeutic approaches based on
transcription factor modulation are already underway, and clinical trials using proton
therapy for pancreatic cancer are underway as well, including a Phase II clinical trial at
Loma Linda University Medical Center.

Importance of Studies
The advent of molecular biology has given scientists powerful tools to understand
the mechanisms and architecture involved in cell structure and function, and has helped
reveal the true complexity of biological systems. A key feature of this complexity is
redundancy, a concept that has plagued therapeutic approaches to cancer. Molecular
biology has revealed that virtually no cellular processes are without pathway redundancy,
and cancer cells have perhaps even more redundancy than normal cells to better equip
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them to evade immune response and death. Gene expression, such as that of survivin, is
affected by redundant epigenetic, transcriptional, and post-transcriptional regulation
factors. In order to most effectively exploit therapy directed against a target such as
survivin, it is important to understand the complete picture of how the survivin gene
works. This dissertation will detail what we believe is a novel regulator of survivin
transcription, YY1. Specifically, YY1 may be a negative regulator of survivin and may
be the focus of therapeutic approaches to cancer therapy in the near future.
In addition to obtaining a more complete understanding of molecular mechanims
involved in oncogenesis and tumor suppression, it is critical to continue to design new
therapeutic approaches based on sound reasoning arrived at through basic science
research. This dissertation also details the use of combined chemotherapy and proton
radiation therapy as a means to treating pancreatic cancer. Since our work began, clinical
trials utilizing combined gemcitabine and proton therapy have been conducted in Japan,
and are showing great promise 85. One of the key limiting factors in radiation treatment
is organ-related or systemic toxicity. Proton therapy is an extremely effective means of
delivery radiation while simultaneously sparing surrounding non-malignant tissue
compared to standard gamma or x-ray radiation 86,87. Currently, proton therapy is not
used as a means of treating pancreatic cancer at Loma Linda Medical Center, but the
work presented in Chapter 3 provides evidence that may stimulate more thought as to
whether or not that should change.
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Abstract
Survivin is a member of the Inhibitor of Apoptosis (IAP) family of proteins, and
is highly expressed in all cancers but absent in most non-proliferative normal tissue.
Expression level correlates with chemo- and radioresistance, as well as poor prognosis in
cancer patients. The mechanisms for upregulation of survivin in cells undergoing stress
associated with tumor development and the tumor microenvironment are not well
understood. The putative stress response transcription factors HIF-1 and Yin Yang 1
(YY1) were hypothesized to contribute to the upregulation of Survivin in tumor cells.
Examination  of  the  5’  flanking  region  of  human  survivin gene revealed the presence of
multiple putative stress activated transcription factor binding domains that have
previously been shown to be associated with HIF-1 and YY1. In order to study basal
regulation with luciferase reporter assays, U2OS cells were transfected with a variety of
constructs of the survivin promoter. As expected, cells overexpressing HIF-1 showed a
2-3 fold transactivation of all promoter constructs tested. Surprisingly, when YY1 is
overexpressed in this survivin promoter reporter system, luciferase expression was
repressed 30-40 fold. YY1 involvement in survivin promoter repression was confirmed
using siRNA directed against YY1. These studies showed that knockdown of YY1
releases the survivin promoter from the observed repression and leads to a 3-5 fold
increase in promoter activity above basal levels. A U2OS cell line containing a stable
YY1 Tet-off system was used to determine whether a temporal increase in YY1
expression affects Survivin protein levels. A low to moderate decrease in Survivin
protein was observed 24 hrs and 48 hrs after Tet removal. Studies also confirmed that
YY1 is capable of directly binding to the survivin promoter. Collectively, these findings
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identify novel basal transcriptional requirements of survivin gene expression. While
HIF-1 may be in part responsible for the increased expression of survivin in tumor
tissue, YY1 may also be induced under stressful conditions to negatively regulate
survivin, suggesting that it is the balance of these transcription factors, and likely others,
that may play an important role in the development of cancer and resistance to its
treatment.

Introduction
Survivin, a unique mammalian inhibitor of apoptosis (IAP) protein, controls stress
from the microenvironment through diverse functions within the cell including
surveillance checkpoints, suppression of cell death, regulation of mitosis, and adaptation
to unfavorable environments 2-4. Unlike all other IAP family members, survivin is unique
in that it has important regulatory roles in both apoptosis suppression and cell cycle
progression regulation 88. Survivin has been observed expressed in most common human
cancers and present during embryonic and fetal development 10. Its aberrant, high protein
expression in cancer cells and concomitantly low expression in most normal tissues
makes survivin an important anticancer target 11. Strategies have been successfully
investigated against survivin, including molecular antagonists such as antisense oligos,
RNA inhibition, ribozymes, dominant negative mutants, survivin-specific cytolytic T
cells, a nonphosphorylatable survivin mutant Thr34 Ala (T34A), triplex DNA formation
and most recently, binding interface mimetics 12-19,89-92.
Epigenetic, genetic and post-translational mechanisms for survivin gene
regulation have been described in many malignant cell types 42 with various transcription
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factors including Stat3 41, HIF-1α  30, Rb-E2F1 93, Dec1 94, Sp1 36, c-myc 95 and KLF5 37
affecting its transcriptional upregulation. In addition, the tumor suppressor p53 and RbE2F2 have been shown to repress survivin transcription by direct binding to the survivin
promoter in a lung adenocarcinoma cell line 96 and in normal human melanocytes 42.
Survivin’s promoter has been recorded to be differentially methylated in ovarian cancers
as compared to normal ovarian tissues. An interesting polymorphism has also been
described at a CDE/CHR repressor element in the survivin promoter that correlates with
increased survivin mRNA and protein in cancer cell lines and not in normal cell line
controls 97.
The transcription factor YY1 is known to have a fundamental role in normal
biologic processes such as embryogenesis, differentiation, replication, and cellular
proliferation 61. YY1 exerts its effects on genes involved in these processes via its ability
to initiate, activate, or repress transcription depending upon the context or recruited
cofactors in which it binds 98,99. One such family of cofactors are the histone
deacetylases which have been shown to bind YY1 and repress transcription when
targeted to promoters 100. YY1 has been shown to interact with p300, PCAF and CBP, all
which posses the histone acetyltransferase (HAT) activity 100. YY1 may thus activate
transcription by its recruitment of HAT proteins and repress trancription by recruiting
HDACs.
Poor oxygenation (hypoxia), owing to an inadequate blood supply, is a common
feature of most solid human tumors and is associated with increased malignancy,
resistance to therapy and distant metastasis 101. Hypoxia inducible factor-1α  (HIF-1α),  a  
member of basic helix-loop-helix-PAS protein family 102,103, is usually increased under
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hypoxic conditions, and can activate transcription of many genes that are critical for
cellular function under hypoxic conditions 102. Previous studies have found that downregulation of HIF-1α  could  significantly  decrease  the  levels  of  survivin  expression  in  
BxPc-3 pancreatic cancer cells 29 and breast cancer cells 30. HIF-1α  was  also  
demonstrated to directly bind to the survivin promoter, which strongly suggests that
survivin gene expression is indeed mediated by HIF-1α  under  normoxic  conditions  30.
In the present study, we examined the transcriptional affect of YY1 and HIF1 on survivin in an osteosarcoma cell line derived from human bone osteosarcoma
(U2OS). We found that when YY1 and HIF-1 were overexpressed in U2OS cells,
survivin mRNA and protein were repressed by YY1 and induced by HIF-1 . By
analyzing the survivin promoter activity, we further found that YY1 was a transcriptional
repressor of the survivin gene while HIF-1α  was a transcriptional activator. We also
show, for the first time, that YY1 is capable of binding directly to the survivin core
promoter and thus is acting as a transcription factor rather than an corepressor.

Results
Identification of Survivin Promoter Sites Involved in Transcriptional
Regulation by HIF-1 and YY1
HIF-1 has previously been shown to be a transcriptional regulator of survivin 28,30,31.
To determine possible bindings sites for YY1, using a computer-based approach the
survivin promoter was scanned for putative HIF-1 and YY1 binding sites using the
online tool TFSearch (www.cbrc.jp/research/db/TFSEARCH.html) and previously
published consensus sequences 104. Figure 1 shows the locations of all identified HIF-1
and YY1 consensus sites in the first 6280 bp of the survivin promoter. Using Survivin
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promoter nested deletions in a luciferase reporter system (previously described by Li and
Altieri 105), the ability of YY1 and HIF-1 to activate or repress survivin promoter activity
was tested (Fig 2. A). The survivin promoter nested deletions were utilized to assist in
identification of regions of the promoter that are essential to regulation of the survivin
promoter by each transcription factor tested. Therefore constructs ranging from 230 bp
upstream of the surviving start site up to 6280 bp upstream of the start site were utilized.
When HIF-1 was overexpressed in U2OS cells, an induction of 2-3 fold was seen in all
constructs tested except +230 bp and +6280 bp. However, when YY1 was
overexpressed, contrary to our initial hypothesis, there was a 30-40 fold repression of
survivin promoter activity in all constructs tested. To further examine these findings, we
evaluated endogenous survivin transcript levels after overexpression of HIF-1 and YY1
in U2OS cells (Fig. 2B). The results were consistent with survivin transcriptional
upregulation by HIF-1 as seen in the previous reporter experiments, and downregulation
of survivin after YY1 overexpression.
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Figure 1. Proximal survivin promoter schematic. Using previously published putative
DNA binding sites for YY1, HIF-1, and TFSearch, the survivin promoter was scanned for
the presence of each of these putative binding sites. Analysis revealed the presence of
multiple putative YY1 binding sites, noted by bolded segments. Similarly, analysis of the
survivin promoter revealed several putative HIF-1 binding sites (noted as the boxed
segments). For reference, putative SP1 sites are also denoted as underlined segments.

26

Figure 2. Effect of HIF-1 and YY1 overexpression on survivin promoter activity and
transcript levels. (A) Luciferase reporter assays were performed using survivin promoter
constructs in the pGL3Basic vector ranging in length from +6280 bp to +230 bp. U2OS
cells were transiently cotransfected with survivin construct DNA of the indicated length,
and either YY1, HIF-1, or their respective empty vector for baseline promoter activity.
Controls indicate relative values of expression when empty pGL3 was contranfected with
empty transcription factor expression vector (Control 1) or empty pGL3 contransfection
with the indicated transcription factor (Control 2). Error bars represent the standard
deviation of duplicate luminescence measurement. Results are representative of repeat
experiments. (B) RT-PCR analysis of survivin expression following overexpression of
YY1 and HIF-1. A (-) indicates that cells were transfected with the corresponding empty
vector for each transcription factor. Beta actin is shown for reference as a loading control.
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siRNA-mediated Knockdown of YY1
Due to the unexpected and robust findings for YY1, it was chosen for further
studies. To provide further evidence for the ability of YY1 to affect basal survivin
promoter activity, YY1 knockdown was performed (Fig. 3 A and B). Because previous
experiments showed survivin promoter activity repression across all constructs tested,
pLuc1430, 393, and 281 were chosen for this experiment. In U2OS (Fig. 3A) and Panc-1
(Fig. 3B) cells alike, siRNA knockdown of YY1 relieved the survivin promoter of basal
promoter activity repression, indicated by an increased in luciferase reporter activity of
approximately 3-4 fold in each construct tested. The overexpression of YY1 again
repressed promoter activity to nearly undetectable levels, a finding consistent with
previously described experiments.
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Figure 3. YY1 siRNA relieves the survivin promoter from transcriptional repression.
Luciferase reporter assays were performed after YY1 overexpression and siRNA
knockdown in (A) U2OS and (B) Panc-1 cells. Three survivin promoter reporter
constructs were tested (pluc1430, pLuc 393, and pLuc 281). Relative expression
indicates promoter activity relative to luciferase activity in the presence of empty pGL3
vector and background pRL-tk activity. Error bars represent the standard deviation of
duplicate luminence measurements. Results are representative of repeated experiments.
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Protein Expression of Survivin is Modulated by YY1 Overexpression
To investigate whether YY1 expression can affect survivin expression at the
protein level, Western blot analysis was done using a U2OS YY1 tet-off cell line
(previously described by Sui et al. 75). Twenty-four hours after tet removal, a significant
YY1 overexpression was seen (Figure 4). Survivin protein levels remained unchanged at
24 hours. However, after 48 hours of incubation in tet-free media, a modest reduction in
Survivin protein expression was seen.

Site-directed Mutagenesis of Putative YY1 Bindings Sites in the
Survivin Promoter
Repression of survivin promoter activity in our luciferase reporter system was
seen in all constructs tested, including the shortest construct containing 230 bp of the
promoter, which has previously been shown to be the core promoter for survivin. Fig. 1
illustrates two putative YY1 binding sites within the first 230 bp of the survivin
promoter, and we therefore wanted to investigate the involvement of these two sites as
key areas involved in repression of basal survivin transcription by YY1. Site-directed
mutagenesis was employed to define the role of these two sites in survivin transcription.
Fig. 5A illustrates the mutation of each CAT region of the putative YY1 sites to GGG.
This region was chosen for mutation based on previous studies indicating that the core
sequence preferred by YY1 is CCAT or ACAT 104. When both putative YY1 binding
sites were mutated, neither overexpression or knockdown of YY1 are able to alter the
basal survivin promoter activity (Fig. 5B). Furthermore, the basal survivin promoter
activity (pcDNA empty vector only) was increased relative to non-mutated promoter
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activity. These data support a role for these putative YY1 binding sites in basal survivin
transcriptional activity.
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Figure 4. Survivin expression decreases after 48 hours of YY1 overexpression. Western
blot analysis of survivin expression after YY1 overexpressionin via tet-off U2OS cells
was analyzed. A) U2OS cells that stably express a YY1 overexpression vector under the
control of a tetracycline responsive promoter were cultured to 70-80% confluency in the
presence of 0.1 mg doxycycline. They were then washed 7-8 times in tet-free media and
cultured for either 24 or 48 hours in tet free media. They were then lysed and protein was
extracted for western blot analysis. +/- indicates the presence or absence, respectively, of
tet in the culture media. (B) Densitometric analysis of Western blot bands. Bars
represent density of YY1 (light bars) or survivin (dark bars) normalized to beta actin
band density.
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Figure 5. Mutation of two putative YY1 binding sites in the proximal survivin promoter
alters promoter activity (A) The two most proximal putative YY1 binding sites
(contained within pLuc230 construct) were mutated from the core YY1 recognition site
CAT to GGG. (B) Luciferase reporter assay. U2OS cells were transfected with either (1)
pLuc230, the standard pGL3 vector containing 230 unmutated bp of the survivin
promoter, or (2) pLucMut in which the two putative YY1 binding sites were mutated
from CAT to GGG. Each vector was cotransfected with either empty pcDNA, YY1, or
YY1 siRNA as well as pRL-tk for transfection efficiency internal control. Error bars
represent standard deviation of duplicate luminescence measurement, and results are
representative of multiple experiments.

35

YY1’s  Interaction  with  the  Core  Survivin  Promoter
YY1 can exert transcriptional changes via direct DNA binding or through proteinprotein interaction. In order to determine if the survivin repression seen in reporter
assays, RT-PCR, and Western blotting is through direct binding of YY1 to the survivin
promoter at locations identified in Fig. 1, electrophoretic mobility shift assay was
performed. Two putative YY1 binding sites located in the survivin core promoter (Fig.
6A) were studied. To validate the study, a YY1 consensus sequence was used (Santa
Cruz Biotechnology, Santa Cruz, CA). Strong YY-1 binding to the consensus sequence
was seen (lane 1, arrow). Supershift (lane 2, asterisk) and cold competition (lane 3)
confirmed the identity and specificity of the YY1 band. When a probe for Site 1 was
used, no binding or supershift was seen (lanes 4-5), indicating that it is not involved in
YY1’s  regulation  of  survivin.    When  a  probe  for  Site  2  was  used,  a  double  band  was  seen  
at the appropriate location, possibly representing two different binding complexes
involving YY1. These bands were supershifted with the addition of YY1 antibody, and
cold competition confirmed the specificity of the results. Binding was enhanced by use
of a probe containing both putative YY1 binding sites (lane 10). Supershift and cold
competitive again confirmed the specificity of the binding (lanes 11-12). These results
indicate that the most proximal putative YY1 binding site located on the survivin
promoter is a target of YY1 binding and regulation, but binding to this site is increased
with the inclusion of the second YY1 recognition site.
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Figure 6: YY1 directly interacts with the survivin promoter. (A) Schematic of survivin
promoter representing regions investigated for YY1 binding. (B) Electrophoretic
mobility shift assay. Nuclear extract was prepared from U2OS cells. 32p labelled probes
(C) were incubated with nuclear extracts either alone (Lanes 1,4,7, 10), with anti-YY1
antibody (lanes 2, 5, 8, 11) or cold competitor (CC) probes in 100x excess (lanes 3, 6, 9,
12). Arrow indicates YY1 bound to probe. * indicates supershift. (C) Probes used in
EMSA, with underlined segments representing putative YY1 binding sites. Result is
representative of two experiments showing similar results.
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Discussion
YY1 is increasingly recognized as a transcription factor that plays an important
role in cancer, although there is a great deal of controversy as to whether YY1 promotes
or inhibits cancer development and progression. While many studies have focused on
YY1 expression levels in tissue samples and the correlation of YY1 levels with clinical
outcomes, metastasis free intervals, and response to therapy, far fewer studies have
identified molecular mechanisms by which this multifunctional transcription factor is
contributing to cancer pathology. We believe that this work shows, for the first time, a
direct role for YY1 in survivin transcription, and that YY1 contributes to reduced basal
expression levels of survivin. However, in the current study the osteosarcoma cell line
U2OS was utilized, and it is therefore unclear if this observed transcriptional repression
of survivin by YY1 is generalizable to a broad array of cancer types. Zhang et al. studied
the role of YY1 on anti-apoptotic factors in colorectal carcinoma and found that siRNAmediated knockdown of YY1 in HCT116 and LOVO cell lines resulted in a decrease in
survivin protein levels and increased levels of apoptosis 106. This is also consistent with
clinical findings of a correlation between high YY1 levels and increased disease
aggressiveness in various cancer types. Indeed de Nigris et al. found that in patients with
osteosarcoma, YY1 overexpression correlated with increased metastasis and poor clinical
outocome 107. They also found that deletion of YY1 in the osteosarcoma cell line SaOS-2
lead to decreased cellular invasion and metastasis, possibly related to VEGF and CXCR4
regulation 108. Other work has found that YY1 levels correlate with longer survival and
decreased invasive potential. In follicular lymphoma biopsy samples, higher expression
levels of YY1 correlated with longer patient survivial 82. Wang et al. (2007) found that
YY1 contributed to the increased expression of the tumor suppressor HLJ1 and related
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decreased in in vitro cancer cell invasiveness. The transcriptional and posttranscriptional network regulation survivin expression is complex (reviewed by Zhang et
al. 109),  and  it  is  therefore  possible  that  downstream  of  YY1’s  downregulation  of  survivin  
transcription other factors are significantly involved in determining the ultimate
expression of survivin and the clinical sequelae that result. It is also important to note
that while our work demonstrates robust surivivin promoter activity reduction via
reporter assay, the resulting reduction in mRNA and protein is more modest. The extent
to which YY1-mediated reduction of survivin expression results in increased apoptosis,
alterations in cell cycle progression, or modulation of other hallmarks of cancer
progression is currently under investigation in our laboratory.
Work by Affar et al. 63 previously showed that in an mouse YY1 knockdown
model, survivin (BIRC5) levels were decreased. This lead us to initially hypothesize that
YY1 overexpression in our hands would show a positive correlation with survivin
expression. We observed instead a robust negative correlation between YY1
overexpression and survivin promoter activity that was also seen, although more
modestly, at the protein level. Interestingly, when the human survivin core promoter
sequence is compared to the mouse survivin core promoter, of note is a lack of homology
at both putative YY1 sites investigated in this study with site-directed mutagenesis (Fig.
7). This may, at least in part, explain why YY1 appears to negatively regulate survivin
transcription in our cell culture model, whereas in mice it may positively regulation
survivin expression.
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Figure 7. Comparison of human and mouse survivin promoter sequences. Boxed
segments represent the 2 putative YY1 binding segments of the survivin promoter
contained within the pLuc230 construct that were mutated in previous experiments.
There is lack of homology between mouse and human at both putative YY1 binding sites
found in the first 230 bp of the survivin promoter. HIF-1α  and  Sp1  bindings  sites  are  
shown for reference.
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We provide several lines of evidence that YY1 represses survivin promoter
activity in U2OS cells. YY1 can regulate targets genes through a host of mechanisms
including protein-protein interactions that allow it to act as a coactivator or corepressor
and by direct DNA binding. In the present study we identified a sequence of the survivin
core promoter containing a putative YY1 binding and went on to show that YY1 is
capable of binding directly to the most proximal of these putative binding sites. Binding
affinity for the survivin promoter was lower than for a consensus sequence known to
efficiently bind YY1 110, and we believe that this likely represents a technical limitation
owing to the extremely high GC content (70-80%) of the survivin promoter. Because of
the highly complicated nature of transcriptional regulatory networks, it is also possible
that a proper scaffold is required for optimal binding. Although YY1 binding occurs at
the most proximal site on the survivin promoter (Site 2), binding is improved by
inclusion of a second putative YY1 binding site (Site 1) that by itself does not appear to
facilitate YY1 binding (see Fig. 6).
There are many proposed models for how YY1 exerts its activating or repressing
effects on promoters (reviewed by Gordon et al. 70), including displacement of
transcriptional activators. Sp1, a known activator of survivin transcription, is also known
to physically interact with YY1 111,112. Known Sp1 binding sites are located in close
proximity to the YY1 binding sites examined in the current study, so it would therefore
be valuable to design future studies to explore the role of Sp1 in YY1-mediates survivin
repression. Also, the known repressor of survivin transcription p53 96,113 is itself
negatively regulated by YY1 75. Therefore future studies should also examine the
interplay of p53 and YY1 expression in survivin transcriptional regulation.
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It was previously believed that targeting of transcription factors as means of
cancer therapy was not practical owing to the complexity of transcriptional networks.
However, it is increasingly believed that drug or small molecule inhibitor-mediated
interruption of transcription factor binding represents an important approach to cancer
therapeutics. The small molecule inhibitor YM155 is currently in phase II clinical trials
for several types of cancer including diffuse large B-cell lymphoma 46, prostate cancer 47,
melanoma 48, and non-small cell lung cancer 49 due  to  it’s  previously  observed  ability  to  
induced apoptosis and reduce tumor bulk in various in vitro and in vivo models 50.
Reduction in survivin transcription after YM155 treatment has been reported 114 and is
believed to be a key mechanism for the apparent sensitization of tumors to cell death that
has been observed.
Our discovery of a novel transcriptional repressor of survivin may provide new
ways of understanding survivin expression in the context of cellular stress resulting from
chemo- and radiotherapy. We also provide evidence for a possible positive role in YY1
overexpression in human cancer. The clinical significance of this finding across different
cancer types has yet to be determined.

Materials and Methods
Antibodies and DNA Vectors
All antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA) unless otherwise indicated. The plasmid expressing YY1 protein, pcDNA3/YY1
as well as the U6/yy1 siRNA and control U6/scrambled were kind gifts of Dr. Sui, Wake
Forest and were described previously 75. Survivin nested deletion constructs were
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previously described 36 and were a kind gift from Dr. Li, Roswell Park Memorial
Institute.

Cell Culture and Transfection
The U2OS human osteosarcoma cell line was obtained from ATCC. U2OS cells with
stable Tet-off YY1 were a kind gift from Dr. Sui, Wake Forest and were previously
described 75. Both cell lines were maintained under an atmosphere of 5% CO2 at 37°C in
McCoys 5A media supplemented with 10% fetal bovine serum, 2 mmol/L of l-glutamine,
and penicillin-streptomycin. The Tet-off cells were additionally maintained in G418,
hygromycin B, and the tetracycline analogue doxycycline (50 ng/mL). YY1 expression
was induced by transferring the cells to Tet-off medium, which is the same as control
(Tet-on) medium except for the lack of doxycycline 75.

Transient Transfection and Reporter Assays
U2OS cells were seeded in 12-well plates and grown to 60 - 80% confluence. A total 0.4
ug of the various survivin promoter-luciferase reporter plasmids were cotransfected with
either 0.6 µg of pcDNA/YY1 or empty vector expression plasmids and 0.01 ug of pRL-tk
using FuGENE 6 (Roche, Indianapolis, IN). Approximately 24h after transfection, cells
were lysed and assayed for luciferase activity by luminometer (Turner Design Systems,
Sunnyvale, CA). Luciferase activity measurement was accomplished according to
manufacturer’s  instructions, with the noted modifications. Briefly, cells were washed in
PBS, pH 7.4, solubilized in 1 x lysis buffer (Promega, Madison, WI) and scraped with a
rubber policeman, then a 5 uL aliquot of the supernatant was mixed with 20 uL of DualGlo® Luciferase Reagent (Promega, Madison, WI) and analysed on a Lumat
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luminometer. 20 uL of Dual-Glo® Stop & Glo® Reagent was then added and a second
reading on the Lumat luminometer was taken. A ratio of luminescence of the first
measurement (pGL3-survivin) to the second measurement (constitutively active pRL-tk)
was calculated and reported for each vector and transcription factor combination tested.
The pLuc230 vector containing CAT GGG mutation used for reporter experiments was
purchased from Origene, Rockville, MD.

Western Blots
Cells were solubilized, proteins (20–40 g) separated using 12 % Bis-Tris
polyacrylamide gels, transferred onto polyvinylidene difluoride membranes (Millipore)
and probed using the following antibodies: mouse monoclonal anti-YY1 (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA), and rabbit polyclonal anti-survivin (Novus,
Littleton, CO). Secondary antibodies (IR-Dye-conjugated) were goat anti-rabbit and goat
anti-mouse immunoglobulin (LICOR, Lincoln, Nebraska). Immunoreactive bands were
detected using the Odyssey imaging system (LICOR) and quantified using ImageQuant
software.

Reverse Transcriptase-PCR
Total RNA was extracted from cells at various time intervals using TRI-Reagent (Sigma,
St. Louis, MO) and reverse-transcribed with SuperScript™  II  RNase  H- Reverse
Transcriptase  (Invitrogen™,  Carlsbad, CA), as described by the manufacturer and
amplified with survivin-specific primers. One hundred nanograms of the resulting firststrand cDNA was used as template and amplified by PCR. Sequences of the
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oligonucleotide primer sets used for reverse transcription-PCR  analysis  are  as  follows:  5′GCA TGG CTG CCC CGA CGT TG -3′  (sense)  and  5′-GCT CCG GCC AGA GGC
CTC AA -3′  (antisense)  for  survivin,  5′-GCT TCG AGG ATC AGA TTC TCA TCC -3′  
(sense)  and  5′- GAC TAC ATT GAA CAA ACG CTG GTC -3′  (antisense)  for  YY1,  5′GCC AGA TCT CGG CGA AGT AAA -3′  (sense)  and  5′- ATA TCC AGG CTG TGT
CGA CTG -3′  (antisense)  for  HIF1,  5′- ATG ACT CGC GAT TTC AAA CCT -3′  (sense)  
and  5′- CTT TGA AGT CGA GAA TCC ATT -3′  (antisense)  for  p75/LEDGF,  and,  5′CTCATGACCACAGTCCATGC-3′  (sense)  and  5′-TTACTCCTTGGAGGCCATGT-3′  
(antisense) for beta actin. Products were visualized on ethidium bromide-stained agarose
gels. Amplification of beta actin served as an internal control.

Electrophoretic Mobility Shift Assay
Nuclear extracts were prepared as previously described 115, with the only modification
that that N-N-(L-3- trans-carboxyoxirane-2-carbonyl)-L-leucyl-agmatine (E64) and 4-(2Aminoethyl)-benzolsulfonyl  ̄ourid  (`Pefabloc  SC')  were  included  as  protease  inhibitors  in  
concentrations suggested by the manufacturer (Boehringer, Mannheim, Germany).
Protein concentration in nuclear extracts was determined using the BCA assay (Pierce)
according to the manufacturers instructions. Oligos used were as follows: Two YY1
sites  (YY1  sites  underlined):    5’- GC GCT CCC GAC ATG CCC CGC GGC GCG
CCA TTA ACC GCC A -3’;;  YY1  Site  1    5’- TG CGC TCC CGA CAT GCC CCG CG 3’;;  YY1  Site  2  CGC GGC GCG CCA TTA ACC GCC A -3’  YY1  Consensus  5’-CGC
TCC CCG GCC ATC TTG GCG GCT GGT-3’.    All  oligos  were  annealed  by  incubating  
at 95% for 2 min, then cooling to room temperature slowly. The DNA-protein binding
reaction was performed in 20 ul reaction mixtures including 10% glycerol, 12 mM
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HEPES ph 7.9, 4 mM TrisHCl ph 8.0, 1 mM EDTA, and 3 ug BSA. Binding reactions
were incubated at room temperature for 30 minutes, then for an addition 60 minutes at 4
degrees C with anti-YY1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA sc-281)
added to the appropriate reactions. The DNA-protein complexes were resolved on 5.5%
non-denaturating polyacrylamidgel (29 : 1 cross-linking ratio), dried and exposed using
the Storm 860 Phosphoimager (Amersham Biosciences).

Statistical Analysis
All data in reporter assay and semiquantitative PCR are presented as means

standard

deviation.
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Abstract
OBJECTIVES: This study evaluates the efficacy of combining proton irradiation
with gemcitabine and the role the inhibitor of apoptosis proteins (IAP) survivin & XIAP
play in the radiosensitive vs. radioresistant status of pancreatic cancer. METHODS: The
radioresistant (PANC-1) and radiosensitive (MIA PaCa-2) pancreatic carcinoma cells
response to combined gemcitabine and proton irradiation was compared. Cells were
treated with 0.1 - 500 M gemcitabine and 0 - 15 Gy proton irradiation after which
Trypan blue and flow cytometry were utilized to determine changes in the cell cycle and
apoptosis. Expression levels of survivin were measured using Western blotting.
Combination therapy with 24 h gemcitabine followed by 10-Gy proton irradiation proved
most effective. RESULTS: Gemcitabine and proton irradiation, resulted in increased
survivin levels, with little apoptosis. However, combination therapy resulted in robust
apoptotic induction with a concomitant survivin & XIAP reduction in the MIA PaCa-2
cells with little effect in the PANC-1 cells. siRNA studies confirmed a role for XIAP in
the radioresistance of PANC-1 cells. CONCLUSIONS: Our data demonstrate that
combining gemcitabine and proton irradiation enhances apoptosis in human pancreatic
cancer cells when XIAP levels decrease. Therefore, XIAP may play an important role in
human pancreatic cancer proton radioresistance.

Introduction
Pancreatic cancer is the fourth most common cause of cancer death in men and
women in the United States, with 5-year survival for all stages of disease less than 5% 116.
Pancreatic cancer has no clear early warning signs or symptoms and is usually silent until
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the disease is well advanced. Patients have a median survival of 4-8 months after
diagnosis due in part to the advanced stage the disease has already attained by the time it
is discovered and treatment has begun. Risk factors include age with diagnosis occurring
in people ages 65-79, smoking, sex, and possibly diets high in fat 117. Currently, if
diagnosed early, surgical resection remains the only viable cure. However, only 20% of
pancreatic cancer patients meet these criteria 118. It is therefore necessary to discover
new therapies or therapeutic combinations in order to significantly impact this deadly
disease. The anti-metabolite agent gemcitabine is currently being employed to treat
pancreatic cancer 119. While gemcitabine has shown significant benefit in clinical
applications, its ability to more than modestly impact pancreatic cancer is limited. It has
been speculated that combinatory treatments using gemcitabine and other
chemotherapeutics or radiotherapeutics could improve survival rates 120,121. Proton
radiotherapy has been investigated for a number of cancer types including cancers of the
prostate, head & neck and brain 122-124. Protocols are also currently in progress or
development for treating a variety of additional cancer types including: carcinoma of the
nasopharynx, paranasal sinus carcinoma, non-small-cell lung carcinoma, hepatocellular
carcinoma and pancreatic cancer 125. Pancreatic cancers though inherently resistant to
photon radiation may be safely treated using protons. Proton therapy allows dose
escalation to improve local tumor control in anatomic sites and histologies where local
control is suboptimal with photons 124. This improved dose localization reduces normaltissue doses resulting in lower acute and late toxicity.
Survivin, a member of the inhibitor of apoptosis protein (IAP) family has
previously been shown to be a prognostic marker for pancreatic cancer patients 84,126,127
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and has also been implicated in cancer cell radio- and chemotherapy resistance 88. Many
recent reports have demonstrated that inhibiting survivin expression by antisense
oligonucleotides 128, dominant negative mutation 14,129, and ribozyme 130 can reduce
cancer cell radio- and chemoresistance and may be important to resensitize these tumors
to therapy.
The goal of this study was to examine the combined affect of gemcitabine and
proton irradiation on the pancreatic cell lines PANC-1 (photon radioresistant) and MIA
PaCa-2 (photon radiosensitive) and to determine whether the same survivin involvement
in proton radiation resistance would be observed129,131,132.

Materials and Methods
Cell Cultures
Pancreatic carcinoma (Panc-1 & MIA Paca-2) cells were obtained from the
American Type Culture Collection (ATCC) and maintained in DMEM supplemented
with 100 units of penicillin, 100 g/ml streptomycin, 300 g of L-glutamine and 10%
heat inactivated FBS (ATCC). MIA PaCa-2 media also included 2.5% horse serum
(ATCC). Cells were grown at 37 °C in a humidified atmosphere of 95% air, 5% CO2.
Gemcitabine or Gemzar

(Eli Lilly and Company, Indianapolis, Indiana) was dissolved

in water and added to cells for the duration of 24 hours prior, simultaneously or 24 hours
after radiation exposure. Post treatment, the cells were returned to the incubator for an
additional 24, 48, or 72 h. All radiation procedures were accomplished in the Loma
Linda University Radiobiology Proton Treatment Facility, now the James M. Slater,
MD, Proton Treatment and Research Center. Cells were exposed in vitro to 250 MeV
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protons with doses ranging from 0 to 15 Gy at four different dose rates: a low dose rate
of 2.5 Gy/h, an intermediate dose rate of 5 Gy/h and two high dose rates of 10 and 15
Gy/h. Cells are treated as shown in Figure 1.

Apoptosis and Cell Cycle Analysis
Subconfluent cultures of the various cell lines were incubated with vehicle
(water), gemcitabine (0 to 500 M) or exposed to proton irradiation (0 to 15 Gy/h) for 0,
24, 48, and 72 hours at 37°C or combinations of gemcitabine and proton irradiation
described above. Cells were harvested, prepared, and analyzed for DNA content as
described previously 133. DNA content was analyzed using a Becton Dickinson FACScan
flow cytometer (Becton Dickinson, San Jose, CA). The distribution of cells in the
different phases of the cell cycle was analyzed from DNA histograms using BD
CellQuest software (Becton Dickinson and Company, San Jose, CA) and FlowJo software
(Tree Star, Ashland, OR).

Western Blot Analysis
Cells were solubilized, proteins (20–40 g) separated using 12 or 15% Bis-Tris
polyacrylamide gels, proteins transferred onto nitrocellulose membranes (Bio-Rad) and
probed using the following antibodies: rabbit polyclonal anti-survivin (Novus, Littleton,
CO) and GAPDH (Cell Signaling Technologies, Beverly, MA), and polyclonal -actin
(Abcam, Cambridge, MA). Secondary antibodies (IR-Dye-conjugated) were goat antirabbit immunoglobulin (LICOR, Lincoln, Nebraska). Immunoreactive bands were
detected using the Odyssey imaging system (LICOR) and quantified using ImageQuant
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software. Protein quantifications presented in this report were normalized with respect to
GAPDH or -actin as indicated.

siRNA Knockdown
siRNA oligos were obtained for Survivin and XIAP knockdown (Santa Cruz
Biotechnology, Santa Cruz, CA). In addition, a scramble siRNA was purchased for
control. Amaxa Nucleofection technology was employed for transfection of PANC-1
cells. PANC-1 cells were cultured as described above and passaged 3 days before
transfection. Nucleofection Kit R was used. PANC-1 cells were trypsinized, counted,
and aliquoted into 1x106 cells per tube. Cells were spun down and resuspended in 100 uL
of nucleofection solution. To this 1.5 ug of siRNA was added, the suspension was
transferred to a nucleofection cuvette, and the suggested program was applied..
Immediately after program completion, 500 uL of fresh media was added and the cells
were aliquoted equally into 6-well plates for further culture and treatment. Cells were
cultured for 3 days after transfection to allow for gene knockdown. After this time, the
appropriate treatments were applied.

Statistical Analysis
Statistical analysis was performed using a two-way analysis of variance
(ANOVA) with the aid of JMP statistical software (Cary, NC). A paired t test was used
for group analysis.
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Results
Gemcitabine-Induced Survivin Protein is Associated with Growth
Inhibition and Cytotoxicity in Pancreatic Cancer Cells
Treatment of PANC-1 or MIA PaCa-2 cells with various concentrations (100 µM,
10 µM and 1.0 µM) of gemcitabine resulted in a modest G0/G1 phase cell cycle arrest at
24 h, followed by the progressive appearance of apoptosis over the 48-72 h time interval
(Figure 2A). Dose escalation of gemcitabine was insignificant, as 1 M was as effective
as 100 M in inducing cell cycle arrest as well as apoptotic cell death in both cell lines.
Between cell lines, the more radiosensitive MIA PaCa-2 cells were also more sensitive to
gemcitabine than the radioresistant PANC-1 cells. Both cell lines in their non-treated
resting state exhibited between a 10 and 20%
polyploid fraction (cells containing greater then 4N DNA). Interestingly, after cells were
gemcitabine treated, this polyploid fraction disappeared in both cell lines (Figure 2A).
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Figure 1. Treatment schematic. Gemcitabine and protons were given at time = 0.
Combination treatment of gemcitabine followed by proton radiation was treated with
gemcitabine given at -24 hrs and then followed by proton irradiation at time = 0  (Gem  →  
Proton). Simultaneous treatment was accomplished with both modalities being given at
time = 0 (Proton + Gem). Proton irradiation was administered 24 hrs before gemcitabine
treatment  at  time  =  24  (Proton  →  Gem).    All  cells  were  harvested  24,  48,  and 72 hrs after
its final treatment was administered.
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Figure 2A. Gemcitabine treatment of PANC-1 and MIA PaCa-2 cell lines. Cells were
treated using 0 M,1 M, 10 M, and 100 M gemcitabine after which they were
harvested and analyzed for DNA content by propidium iodide staining and flow
cytometry at 24 hr, 48 hr, and 72 hr. Percentages of apoptotic cells with hypodiploid
(sub-G1) DNA content as well as those in G0/G1, S, G2/M and polyploid are indicated per
each condition tested. Data are the mean
SD of three independent experiments
(*p<0.01, **p<0.001).
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Figure 2B. Detergent-solubilized extracts of pancreatic cells treated with gemcitabine
were analyzed at the indicated time intervals for reactivity with antibodies for survivin
and GAPDH (loading control), by Western blotting. Molecular-weight (Mr) markers in
kilodaltons are shown on the left.
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Treatment of both PANC-1 and MIA PaCa-2 cell lines for 24 h with gemcitabine
resulted in a dose-dependent reduction in survivin levels by Western blot analysis (Figure
2B). Further gemcitabine incubation of 48 h and 72 h resulted in survivin protein levels
being enhanced or unchanged at doses of 1 and 10 M in both cell lines, a result that is
most likely due to drug-induced stress 134. As a dose of 10 M gemcitabine induced a
time dependent G0/G1 arrest, enhanced cytotoxicity and 24 h reduction in survivin, this
dose was chosen for all further experiments with MIA PaCa-2 cells. However, PANC-1
cells were treated with 100 M gemcitabine due to their resistance to gemcitabineinduced cell death.
Treatment of PANC-1 or MIA PaCa-2 cells with various concentrations (0, 2.5, 5,
10, and 15 Gy) of proton irradiation resulted in significant cell cycle arrest in both the
radiosensitive MIA PaCa-2 as well as the radioresistant PANC-1 pancreatic cell lines in a
dose-dependent manner (Figure 3A). Unlike the results of gemcitabine in these two cell
lines, only the radiation sensitive MIA PaCa-2 cells were induced to undergo notable
levels of apoptosis. MIA PaCa-2 cells experienced a time and dose-dependent apoptosis
with the G2/M arrested cells being the most sensitive as it is from this population of cells
that the highest level of time-dependent death is recorded. Photon radioresistant PANC-1
cells were also resistant to proton radiation (Figure 3A) even though these cells also
experienced a dose-dependent cell cycle arrest. In both cell lines, proton radiation
induced a dose-dependent increase in polyploid cells from the 10% observed in the
untreated controls to almost 30% in those treated with 15 Gy (Figure 3A).
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Figure 3A. Proton irradiation of PANC-1 and MIA PaCa-2 cell lines. Cells were treated
using 0, 5, 10 or 15 Gy of proton radiation after which they were harvested and analyzed
for DNA content by propidium iodide staining and flow cytometry at 24 hr, 48 hr, and 72
hr. Percentages of apoptotic cells with hypodiploid (sub-G1) DNA content as well as
those in G0/G1, S, G2/M and polyploid are indicated per each condition tested. Data are
the mean SD of three independent experiments (*p<0.01, **p<0.001).
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Figure 3B. Detergent-solubilized extracts of pancreatic cells treated with proton radiation
were analyzed at the indicated time intervals for reactivity with antibodies for survivin
and -actin (loading control), by Western blotting. Molecular-weight (Mr) markers in
kilodaltons are shown on the left.
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Treatment of both MIA PaCa-2 and PANC-1 cells lines with proton radiation
resulted in a dose-dependent increase in survivin protein as defined by Western blot
analysis (Figure 3B). This increase in survivin protein concomitant with the observed
G2/M arrest is expected as survivin has been previously shown to be expressed during
cell division in a cell cycle-dependent manner 134.

Sequential Treatment of Pancreatic Cancer Cells with Gemcitabine
and Proton Irradiation Enhances the Effect of Single Agent Treatment
in only MIA PaCa-2 Cells
Treatment of MIA PaCa-2 cells with 10 M gemcitabine (Figure 2A) and 10 Gy
proton radiation (Figure 3A) resulted in modest levels of apoptosis, cell cycle arrest and
survivin modulation in both cell lines with the most prominent killing effect in MIA
PaCa-2 cells. We therefore combined the two modalities as shown in Figure 1.
Treatment of MIA PaCa-2 cells (Figure 4A) with 10 M gemcitabine or 10 Gy
proton irradiation resulted in cell cycle arrest at G0/G1 and G2/M respectively. For
sequential treatments that include gemcitabine as the first modality in the treatment
regimen, G0/G1 arrest was also the prominent phenotypic cell cycle change and likewise a
G2/M arrest resulted from sequential treatments that used proton irradiation as the first
modality in the treatment regime. Cell cycle arrest was followed by the progressive
appearance of apoptosis over the 72 h time interval. However, sequential treatments
where gemcitabine lead proton irradiation resulted in an enhanced apoptosis by 48 h, a
trend that increased further by 72 h. An interesting observation first made with the single
agent treatment experiments (Figure 2 & 3) is that gemcitabine treatment does not result
in significant numbers of cells having greater than 4N DNA (polyploidy) while proton
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irradiation results in a progressive accumulation of polyploid cells. This is also observed
in the sequential treatments where proton irradiation leads gemcitabine treatment.
However, where gemcitabine and proton are given concurrently, little enhancement of
this polyploid fraction is recorded and where gemcitabine leads the proton irradiation, an
unremarkable number of polyploid cells are recorded (Figure 4A).
Like MIA PaCa-2 cells, treatment of PANC-1 cells (Figure 4B) with 100 M
gemcitabine or 10 Gy proton irradiation alone or those combinations that lead with
gemcitabine or proton irradiation also resulted in cell cycle arrest in G0/G1 and G2/M
respectively. However, unlike MIA PaCa-2 cells, sequential treatments did not result in
the progressive appearance of apoptotic cells, even though 10 fold higher concentration
of gemcitabine was used. In fact, after 72 h of treatment, no significant changes are
observed from those recorded after only 24 h of treatment. Polyploidy does however,
match what was observed in the MIA PaCa-2 cells (Figure 4A).
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Figure 4A. Combination Gemcitabine and Proton Radiation in PANC-1 and MIA PaCa2 cell lines. (A) PANC-1 and (B) MIA PaCa-2 cells were treated using 10 Gy of proton
radiation and 10 M gemcitabine after which they were harvested and analyzed for DNA
content by propidium iodide staining and flow cytometry at 24 hr, 48 hr, and 72 hr.
Percentages of apoptotic cells with hypodiploid (sub-G1) DNA content as well as those
in G0/G1, S, G2/M and polyploid are indicated per each condition tested. Data are the
mean SD of three independent experiments (*p<0.01).
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Figure 4B. Combination Gemcitabine and Proton Radiation in PANC-1 and MIA PaCa2 cell lines. (A) PANC-1 and (B) MIA PaCa-2 cells were treated using 10 Gy of proton
radiation and 10 M gemcitabine after which they were harvested and analyzed for DNA
content by propidium iodide staining and flow cytometry at 24 hr, 48 hr, and 72 hr.
Percentages of apoptotic cells with hypodiploid (sub-G1) DNA content as well as those
in G0/G1, S, G2/M and polyploid are indicated per each condition tested. Data are the
mean SD of three independent experiments (*p<0.01).
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Modulation of Survivin Protein Expression by Combining
Gemcitabine and Proton Irradiation in Pancreatic Cancer Cell Lines
To determine the potential relevance of targeting survivin for tumor cell apoptosis
in sequential gemcitabine and proton irradiation treatments, survivin levels were analyzed
by Western blotting in PANC-1 and MIA PaCa-2 cells treated with gemcitabine or proton
irradiation alone or with the sequential combinations described previously at 48 h post
treatment (Figure 1). Treatment of PANC-1 cells with gemcitabine or protons resulted in
a 2 and 4 fold increase in survivin expression respectively (Figure 4C).
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Figure 4 C & D. Detergent-solubilized extracts of (C) PANC-1 and (D) MIA PaCa-2
cells treated with 10 Gy of proton radiation and 10 M gemcitabine were analyzed at 48h
for reactivity with antibodies for survivin and -actin or GAPDH (loading control), by
Western blotting.
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Figure 4 E & F: (E) PANC-1 and (F) MIA PaCa-2 membranes were stripped and
reprobed with antibodies for XIAP after which densitometric fold changes for each were
indicated below. Molecular-weight (Mr) markers in kilodaltons are shown on the left.
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In contrast, treatment of MIA PaCa-2 cells only showed a 2 to 3 fold increase in
those cells treated with protons. Gemcitabine treatment for 48 h resulted in a down
regulation of survivin protein (Figure 4D). Both cell lines exhibited very little change in
survivin protein expression from that of the control in the sequential combination
treatments (Figure 4C, D). XIAP has been known to interact more directly with the
apoptotic pathway machinery than survivin 135. Both cell lines also exhibited very little
change in XIAP protein expression compared to control, with the noticeable exception of
gemcitabine  →  proton  treatment  (Figure  4E,  F).    This  sequential  treatment  showed  a  
marked decrease in XIAP protein expression, which may be responsible for the MIA
PaCa-2 cells being more susceptible to the combination of gemcitabine and proton
irradiation then the PANC-1 cells.

siRNA Knockdown of XIAP Further Potentiates Cell Death After
Gemcitabine and Proton Combination Therapy
To further investigate the role survivin and XIAP may play in proton radiation
resistance of the PANC-1 cells, siRNA knockdown experiments were completed. Three
days after transfection with the siRNAs (described in Materials and Methods), cells were
analyzed for the presence of Survivin and XIAP knockdown. PCR analysis indicated that
survivin and XIAP knockdown was successful (Figure 5A), with approximately 75%
knockdown of XIAP and 40% knockdown of Survivin.
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Figure 5. Knockdown of the inhibitor of apoptosis proteins survivin and XIAP, using
siRNA, increases drug and radiation killing of PANC-1 pancreatic cancer cells. (A)
Knockdown of survivin and XIAP expression. PANC-1 cells were transfected with
either Scrambled siRNA or siRNA designed to knockdown survivin or XIAP.

74

Furthermore, after 72h IAP knockdown, cells were treated with either gemcitabine,
proton radiation, or 24h gemcitabine followed by proton radiation (Figure 1). Forty-eight
hours after treatment, cells were harvested for propidium iodide flow cytometric analysis.
As hypothesized, the addition of the XIAP siRNA to the PANC-1 cells resulted in a
marked increase in gemcitabine/proton-induced apoptosis compared to that recorded in
the cells having survivin knockdown or those of the control (Figure 5B).
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Figure 5B. (B) PANC-1 cells were first transfected with siRNA against either survivin or
XIAP for 12 h after which they were treated using 10 Gy of proton radiation and 10 M
gemcitabine. Cells were harvested and analyzed for DNA content by propidium iodide
staining and flow cytometry at 48 hr. Percentages of apoptotic cells with hypodiploid
(sub-G1) DNA content as well as the polyploid are indicated per each condition tested.
Data are the mean SD of two independent experiments.
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Discussion
There has been little success in developing effective systemic therapies for the
treatment of patients with locally advanced or metastatic pancreatic cancer.
Chemotherapy was first combined with radiotherapy in the treatment of pancreatic cancer
when clinicians at the Mayo Clinic in 1969 added 5-Fluorouracil (5-FU) to external beam
radiotherapy. The result was an improved mean survival of 10.4 months for the
combination therapy compared to 6.3 months for those patients receiving radiotherapy
alone 136,137. As a result, this combination has been considered standard therapy for
locally advanced pancreatic cancer 137 and though multiagent regimens which include 5FU have sought to improve upon this combination, randomized phase III trials have
failed to confirm survival advantage over that with 5-FU alone 138. More recently, the
nucleoside analog gemcitabine provided encouraging results in both antitumor effects and
its impact on parameters of clinical benefit for patients with pancreatic cancer such as,
decreased pain severity, decreased requirement for opioid analgesics, increased appetite
and weight gain 138. In direct comparison on locally advanced pancreatic cancer and
metastatic pancreatic cancer, gemcitabine treatment resulted in a 5.56 month overall
survival compared to a 4.41 month overall survival using 5-FU. In combination with
conventional radiotherapy gemcitabine extended overall survival to 11.3 months
compared to 5-FU extending it by 10.4 months 137,138. As a result, gemcitabine has
become widely accepted for unresectable pancreatic cancer.
As pancreatic tumors are well advanced before detection, with survival reduced
due to high rates of distant metastases, the continued use of conventional radiation-based
therapies has been brought into question. As tumor loads increase, superfluous radiation
delivered to surrounding normal tissue leads to increasing treatment morbidity. As a
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result, better control of dose distribution and localization are necessary. Proton
radiotherapy allows for both. Where local control is suboptimal with conventional
photon radiotherapy, proton radiotherapy provides improved physical dose distribution,
and improved localization to anatomic sites and histologies. The resulting improvements
to both dose distribution and localization will ultimately lead to dose escalation for
anatomical sites where local control with conventional radiation dose has been
suboptimal such as in advanced pancreatic disease 125,139.
The aim of the current work was to define the involvement of survivin following
chemotherapy and radiation therapy and to determine if proton irradiation followed
classical radiation treatment observations. Our data shows that proton irradiation alone
exhibited similar results as has been reported in photon radiation treatment. However,
sequential treatment using gemcitabine before proton irradiation induced significant
apoptotic cell death. While survivin seems to be minimally involved in the mechanism of
radioresistance, our work provides evidence that XIAP down regulation may be involved
in the sensitization of MIA PaCa-2 cells and the concomitant radioresistance of PANC-1
cells. It has been demonstrated that RNAi-mediated knockdown of XIAP as well as
small molecule inhibitors of XIAP sensitize pancreatic cancer cells to apoptosis via
activation of caspases 2, 3, 8 and 9, and loss of mitochondrial membrane polarization 140.
Furthermore, XIAP small molecule inhibitors have been shown to synergize the effects of
radiation and gemcitabine alone 141.
An important finding of these studies was the treatment of PANC-1 and MIA
PaCa-2 cells with proton irradiation caused a significant number of the cells to become
polyploid. Polyploidy is a state in which cells possess more than two sets of homologous
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chromosomes. It is commonly believed that polyploid cells arise after cellular stress,
ageing, and in various diseases, perhaps because polyploidy confers a metabolic benefit
142-144

. Polyploid cells have been shown to be genetically unstable and can be the

intermediates where aneuploid cells become cancerous 144. In our hands, treatment of the
pancreatic cancer cells lines with proton irradiation alone or before being combined with
gemcitabine resulted in a significant enhanced polyploid fraction of cells (Figure 4). The
cells treated with gemcitabine alone or with gemcitabine followed by proton irradiation
prohibited this polyploidy. These findings suggest that proton irradiation-resistant
pancreatic cells may gain enhanced genetic instability and ultimately a more aggressive
tumor phenotype. However, administering gemcitabine as a pretreatment to proton
irradiation may reduce this genetic instability and ultimately allow the proton irradiation
to result in a more effective killing of the tumor. Furthermore, as polyploidy is a state of
having more than two sets of chromosomes, survivin is a chromosomal passenger protein,
and its deregulation in cancer promotes tetraploidy or aneuploidy, we strongly believe
that by better understanding the role of gemcitabine and proton irradiation biology in
regard to survivin expression modulation will provide useful data for the combining of
therapies for the killing of radioresistant pancreatic cancer.
XIAP, a unique and best-characterized member of the inhibitor of apoptosis (IAP)
family, has been identified as a central regulator of caspase-dependent apoptosis.
Whether the activation of apoptosis is initiated by events that perturb the mitochondria
(via caspase-9) or progress directly from cell surface receptors (via caspase-8), the ability
of XIAP to inhibit the downstream executioner caspases-3 and -7 makes it a potent and
broad inhibitor of cell death145 and important target for therapy. XIAP reduction has
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been reported in cells treated with protons and hypoxia in three kinds of cancers: lung,
hepatoma and leukemia146. However, pancreatic cancers were not investigated. A
broadened search to include photon and UV radiation revealed that much work has been
accomplished investigating radiation-induced downregulation of XIAP and the
mechanisms whereby this happens. A recent study describes UVB-induced sensitization
coinciding with XIAP degradation which then allows for functional caspase 3-induced
apoptosis147. Furthermore, the loss of XIAP was shown to be the result of UVBenhanced Ikappa B alpha degradation, resulting in NF-kappaB-dependent transcriptional
repression of XIAP147. Future  studies  will  explore  XIAP’s  involvement  in  the  sequential  
chemo- and  radiosensitization  of  pancreatic  cancer  as  well  as  survivin’s  role  in  XIAP  
stabilization and the possibility of shifting the survival phenotype to apoptosis by
interfering with this union.
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CHAPTER FOUR
DISCUSSION
This work demonstrates a role for YY1 in the transcriptional regulation of
survivin, an important target in cancer therapeutics. Contrary to our initial hypothesis,
YY1 was shown to downregulate survivin promoter activity. The second part of this
work shows that, at least in principle, decreased expression of IAPs such as survivin and
XIAP through a combination of chemotherapy with proton radiotherapy may increase the
sensitivity of tumors to cell death. While the latter aspect of the dissertation has a clear
implication in cancer therapy, the former aspect may draw criticism from the cancer
biology community owing to its lack of application to the specific approaches to cancer
treatment. In the past this criticism may have been more relevant, but current approaches
to cancer therapy are beginning to include transcription factors as very valid targets of
cancer therapy. As previously mentioned, Hanahan and Weinberg have produced
seminal work summarizing the hallmarks of cancer 148. These hallmarks include (1)
evasion of programmed cell death, (2) insensitivity to growth-inhibitory signals, (3)
limitless replicative potential, (4) sustained angiogenesis, (5) self-sufficiency in growth
signals, and (6) tissue invasion and metastatic spread. They more recently proposed two
emerging hallmarks that include 1) evasion of immune destruction and 2) deregulation of
cellular energetics 149. A review by Mees et al. has eloquently summarized how a variety
of transcription factors play direct roles in each of these hallmarks of cancer in hopes of
furthering a shift in thinking that embraces targeting of transcription factors in cancer
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therapy 150. Among the many transcription factors discussed, several are worth noting in
greater detail here given their relevance to survivin and YY1. Table 3 summarizes
several transcription factors with specific relevance to survivin and YY1.
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Table 3: Transcription Factors Involvement in Hallmarks of Cancer and Their
Relationship to Survivin and YY1 (adapted from Mees et al. 150).
Transcription Factor/Target
NF- B

Androgen receptor

Myc
p53
HIF-1
Sp-1

Hallmark of Cancer
Sufficiency in growth
signals

Rationale

Constiutively active in
many cancers. Positively
regulates survivin
transcription.
Sufficiency in growth
YY1 directly interacts with
signals
AR and enhances AR
interaction with PSA
promoter.
Insensitivity to growthYY1 activates c-myc
inhibitory signals
promoter
Evasion of programmed cell Survivin downregulated by
death
p53. YY1 downregulates
p53.
Sustained angiogenesis
Positively regulates survivin
transcription
Sustained
Transcriptional activator of
angiogenesis/evasion of
survivin. Interruption of
programmed cell death
Sp-1 binding to survivin
promoter induces cell death
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Therapeutic Potential of YY1 in Cancer Therapy
The role of survivin in therapeutic approaches to cancer remains promising, as
there are ongoing efforts to target it in new and innovative ways. Although the role of
YY1 in cancer has been known for a while now, efforts to exploit it for therapy are in
their relative infancy. Just as the role of YY1 in cancer biology is controversial, so is its
value in therapeutic approaches to cancer. In ovarian cancer patients, one group found a
positive correlation between YY1 expression and response to taxane therapy. In this
study, YY1 knockdown lead to a significant reduction in cell proliferation and
anchorage-independent growth as well as increased effectiveness of the drug paclitaxel 78.
This is postulated to be because of positive regulation of genes involved in microtubule
stabilizing activity. TRAIL is a promising ligand for inducing cell death in clinical
applications because it has been shown to induce anti-tumor activity while sparing
nonmalignant tissue 151. TRAIL induces cell death by binding to death receptors DR4 or
DR5 with subsequent activation of caspases. Baritaki et al. 152 showed that siRNAmediated knockdown of YY1 results in increased DR5 expression and sensitization to
TRAIL-mediated apoptosis. YY1 is capable of directly binding to the DR5 promoter to
downregulate its expression 153. They also show that treatment of prostate cancer cells
(PC3) with the nitric oxide donor DETANONOate sensitizes cells to TRAIL-induced cell
death by downregulating NF B and downstream of that YY1. The same group has
shown that inhibition of the anti-apoptotic factor BCLXL is also involved, but it is
unknown if this is via regulation of BCLXL by YY1. This represents another line of
evidence that interruption of YY1 activity has potential for sensitization of tumors to
chemotherapy and other treatment modalities. Given  the  controversy  as  to  YY1’s  role  in  
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cancer, this will result in significant challenges in understanding how to approach
individual types of cancer therapy as it relates to inhibition of YY1. This will require that
targeting of YY1 be highly cancer specific to avoid dysregulation of YY1 in normal
tissue.

YY1 and Survivin: Beyond Transcriptional Regulation
Tumor metastasis is the most common cause of death in cancer patients. It is a
remarkably complex process with several several steps described by Hanahan and
Weinberg that are required for a malignant cell to fully metastasize 148. The first step is
invasion, which involves the loss of cell adhesion molecules. Without loss of surface
adhesion molecules it is not possible for a cell to begin migration into neighboring tissue.
The second step involves intravasation of the invading malignant cells into the blood or
lymphatic system. The third step, which only a small percent of intravasated cells are
though to be able to accomplish, is extravasation through capillaries at a site distant to the
primary tumor. Once extravasated, cells must then regain adhesion molecules that allow
the cell to establish the ability to survive in the new environment. In carcinomas, the
metastatic process is thought to consist of a number of distinct steps. The complex
mechanisms required to accomplish each of these steps are the subject of intense
research.
Epithelial-to-Mesenchymal Transition (EMT) is a proposed mechanism by which
malignant cells initiate the need for a loss of adhesion molecules so that invasion can take
place. EMT is characterized by a loss of E-cadherin  and  β-catenin, and a gain in Ncadherin and vimentin expression (reviewed by Huber et al. 154). The transcription
factors Twist, Snail, and Slug have been identified as the major regulators of these
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adhesion molecules 155-157. Research from our laboratory indicates that survivin is
involved in the invasion step of metastasis 158.
Survivin is overexpressed in primary tumors in addition to distant metastatic cells,
however no direct involvement in the mechanism of metastasis has been identified. Our
lab has recently found a novel means by which survivin promotes cell invasion.
Extracellular survivin is able to promote invasion of HeLa cells through a collagen
matrix, and antibody depletion of survivin abrogates this increased cell invasion 158.
Studies are ongoing to identify mechanisms behind this observation. Very recently Yie et
al. 159 found that patients with survivin-expressing circulating non-small cell lung cancer
cells had a higher instance of cancer recurrence and increased follow-up lymph node
involvement. Other studies have shown that survivin is able to delineate node positive
from node negative rectal cancer 160. In small cell adencarcinoma of the lung, patients
with histological evidence of high survivin expression had more evidence of veinous
invasion of malignant cells, and overall patients with high survivin expression had
decreased survival 161. In squamous cell carcinomas, survivin expression correlates with
high grade, poorly differentiated tumors and with increased lymph node metastasis 162. A
common theme in these studies is the presence of almost entirely correlative data with
little or no mechanistic information.
Among the many target genes of YY1 being discovered, some involved in
metastasis are now being identified. A report in 2005 hypothesized that cooperation of
YY1 and AP-1 may increase the repression of the galactocerebrosidase (GALC) gene.
GALC is an enzyme that is overexpressed on the surface of cancer cells. Suppression of
this enzyme leads to an accumulation of galactocerebroside, which results in a decrease
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in cellular adhesion and inhibition of apoptosis. This in turn leads to increased cell
proliferation and migration 163. This observation, although it was largely conjecture, was
the first evidence that YY1 may be involved in cancer invasion and metastasis. However,
in the search to identify new genes involved in metastasis suppression, Wang et al. (2005)
discovered that HLJ1, a metastasis suppressor, is positively regulated by YY1 164. High
levels of YY1 expression correlated with HLJ1 expression , and promoter reporter assays
indicated that YY1 was acting directly on transcription of HLJ1. Subsequent studies
found that a synergistic relationship between YY1 and AP1 lead to a 5 times higher
activation of HLJ1 and much more potent in vitro cancer cell invasion 165. Using the
osteosarcoma cell line SaOS-2, de Negris et al.64 found that deletion of YY1 leads to a
decrease in cell invasion in vitro and decrease metastasis in vivo. Deletion of YY1 also
correlated with a decrease in vascular endothelial growth factor (VEGF) and
angiogenesis. They also identified a host of genes involved in cell motility, cell cycle,
cell adhesion, angiogenesis, and signal transduction that exhibited significant changes
when YY1 was deleted 64. One report suggested that YY1 is a regulator of Snail, one of
the key transcription factors responsible for regulation of EMT, a key feature of
metastasis 166. Together these  data  detail  the  complicated  nature  of  YY1’s  involvement  
in cancer metastasis, as it appears that in some types of cancer it may inhibit metastasis,
while in others such as osteosarcoma it may promote metastasis and aggressiveness of the
disease.

Future Directions
The work presented here illustrates a role for YY1 in survivin transcriptional
repression in the osteosarcoma cell line U2OS. However, the role of YY1 in
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transcription of survivin in other cancer types has yet to be thoroughly investigated.
Preliminary  evidence  from  our  laboratory  indicates  a  similar  repressive  role  for  YY1’s  
observed repression of survivin in the pancreatic cancer cell line Panc-1. In Chapter 3,
data was presented that indicated an important role for survivin expression levels in Panc1 radioresistance, but it suggested an even larger role for the inhibitor of apoptosis XIAP
in the radioresistance of PANC-1 cells. Therefore, future studies should broaden the
investigation of cancer-specific YY1 regulation of survivin transcription and be expanded
to investigation of transcriptional regulation of IAPs such as XIAP.
The work presented in Chapter 2 shows multiple avenues of evidence for the
involvement of YY1 involvement in basal survivin transcription, but future efforts should
attempt to identify the role of YY1 in cellular response to stresses in the form of
chemotherapeutics, radiotherapy, or natural agent exposure. HIF-1 ’s  role  in  survivin  
transcriptional upregulation is now well established 30,31. While YY1 is not clearly
established as a stress-response transcriptional factor per se, several studies have
indicated that is involved in unfolded protein response and resulting ER stress 167 and
may even inhibit the function of p53 in response to genotoxic stress 168.
In  keeping  with  the  need  to  better  understand  YY1’s  role  in survivin-mediated
cellular stress response, it is also critical for future studies to measure functional
outcomes as a consequence of survivin transcriptional modulation. Preliminary evidence
in our lab indicates that YY1 overexpression in U2OS tet-off cells may be involved in
enhanced cellular proliferation as measured by the Ki-67 assay (unpublished data).
However, it is unknown the extent to which YY1 overexpression is specifically involved
in this enhanced proliferation or if it is indeed mediated by survivin or by one of the other
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numerous transcriptional targets of YY1. The reporter data presented in Chapter 2
indicates very robust repression of survivin promoter activity when YY1 is
overexpressed, but much more moderate reduction in protein expression. A recent study
was able to show a role for YY1 in mammary cell proliferation, migration, clonogenicity,
invasion, and tumor formation, and they identified YY1-mediated p27 degradation as a
likely mechanism behind this 169. In a similar fashion, future work should elucidate
whether YY1 is able to modulate cellular invasion, migration, proliferation, and other
outcomes through its regulation of survivin. These studies will be critical to further
efforts to establish new therapeutic approaches based on survivin targeting.
Our lab has recently described a novel pool of survivin existing in the
extracellular space 158. Current studies are exploring ways in which this pool of survivin
may contribute to disease in the normal neighboring cells in the tumor microenvironment.
Antibody depletion of this extracellular pool of survivin may prove to be a valid
therapeutic approach for solid tumors. However, at this point the mechanism for export
of survivin in unknown and under investigation. If YY1 is indeed a modulator of
survivin transcription, it stands to reason that YY1 overexpression or knockdown may
alter the amount of survivin that is exported to the extracellular space.

Summary and Conclusion
Cancer is a disease that is increasingly being understood to be a constellation of
hundreds if not thousands of different diseases. This is likely why, despite a multitude of
significant advances in our understanding of cancer, current therapies leave much to be
desired in terms of patient health and well being. The future of cancer therapy will
hopefully include personalized approaches to individual disease, but this will require a
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more complete understanding of the underlying factors involved in cancer development
and advancement. The work described in this dissertation will serve as a small, but
perhaps important, addition to the body of knowledge regarding survivin transcription
and the role of survivin and other IAPs in resistance to death induction by presently used
chemotherapeutics and radiotherapy techniques.
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